• Daniel Engelman, Paul T Cantey, Michael Marks, Anthony W Solomon, Aileen Y Chang, Olivier Chosidow, Wendemagegn Enbiale, Dirk Engels, Roderick J Hay, David Hendrickx, Peter J Hotez, John M Kaldor, Mike Kama, Charles D Mackenzie, James S McCarthy, Diana L Martin, Birhan Mengistu, Toby Maurer, Nebiyu Negussu, Lucia Romani, Oliver Sokana, Margot J Whitfeld, L Claire Fuller, and Andrew C Steer.
• Tropical Diseases Group, Murdoch Children's Research Institute, Melbourne, VIC, Australia; Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia; Department of General Medicine, Royal Children's Hospital, Melbourne, VIC, Australia. Electronic address: daniel.engelman@rch.org.au.
• Lancet. 2019 Jul 6; 394 (10192): 819281-92.

AbstractScabies is a parasitic disease of the skin that disproportionately affects disadvantaged populations. The disease causes considerable morbidity and leads to severe bacterial infection and immune-mediated disease. Scientific advances from the past 5 years suggest that scabies is amenable to population-level control, particularly through mass drug administration. In recognition of these issues, WHO added scabies to the list of neglected tropical diseases in 2017. To develop a global control programme, key operational research questions must now be addressed. Standardised approaches to diagnosis and methods for mapping are required to further understand the burden of disease. The safety of treatments for young children, including with ivermectin and moxidectin, should be investigated. Studies are needed to inform optimum implementation of mass treatment, including the threshold for intervention, target, dosing, and frequency. Frameworks for surveillance, monitoring, and evaluation of control strategies are also necessary.Copyright © 2019 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Published by Elsevier Ltd.. All rights reserved.

10 keywords...

hide…